TABLE 6.

Impact of carbapenem resistance in Acinetobacter spp. on mortality, LOS, and hospital costs

Type of study showing an impact of resistanceSettingInfectionNo. of cases/no. of controlsParameterMain findingsSignificance (P value or 95% CI)Reference
Case-controlTertiary careNosocomial10/10MortalityCases, 34%; controls, 27%P > 0.059
LOSCases, 31.5 days; controls, 13 daysP = 0.02
Case-controlTertiary careBurn patients34/43MortalityCases, 26.5%; controls, 0%P < 0.0182
LOSCases, 32.5 days; controls 21 daysP < 0.01
Case-controlTertiary careBurn patients34/183LOSCases, 36.8 days; controls, 25.6 daysP = 0.0681
CostCases, $98,575 higherP < 0.01
Case-controlTertiary careBSI40/40aMortalityCases, 57.5%; controls, 25.7%P = 0.00739
Case-controlICUNosocomial infections34/68aMortalityOR,b 3.91.4-10.761
LOSCases, 30 days longer11-38 days
Case-controlICUColonization32/63aLOS (ICU)Cases, 19 days longer5-28 days61
  • a Studies with either matched controls or multivariate analysis, in order to minimize confounding.

  • b OR, odds ratio.